Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Helena Meyer

Foot and Ankle Surgery Dartmouth, MA Doctor of Osteopathy

NPI 1619265238 CMS profile 1121162

531 Faunce Corner Rd, Dartmouth, MA 02747

Open in the dashboard

General payments

$12,354

60 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Helena Meyer of Dartmouth, MA is reported in the CMS Open Payments database as having received $12,354 across 60 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Foot and Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,386 20
2024 General $1,466 8
2023 General $927 10
2022 General $2,434 4
2021 General $3,148 15
2020 General $559 1
2019 General $1,433 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Helena Meyer
  • Foot and Ankle Surgery median
  • Middle half of Foot and Ankle Surgery
  • National median

In program year 2025, general payments to Helena Meyer were reported at $2,386. Among 650 Foot and Ankle Surgery profiles paid that year, the median was $1,183 and the middle half received between $267 and $6,309.

Show as a table
Year Helena Meyer Foot and Ankle Surgery median Middle half National median
2019 $1,433 $1,327 $279–$5,421 $163
2020 $559 $795 $121–$3,473 $114
2021 $3,148 $1,289 $201–$4,963 $132
2022 $2,434 $1,539 $270–$6,067 $149
2023 $927 $1,117 $257–$5,264 $160
2024 $1,466 $1,064 $235–$4,944 $164
2025 $2,386 $1,183 $267–$6,309 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Kairos Surgical Inc $5,961 10 payments
  2. Stryker Corporation $2,633 20 payments
  3. Arthrex, Inc. $2,403 21 payments
  4. Coastal Technology Solutions LLC $1,313 8 payments
  5. AxoGen $45 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $6,642 6 payments
  2. Travel and Lodging $4,597 20 payments
  3. Food and Beverage $1,114 34 payments
Products named General payments · program years 2019–2025
  1. PROSTEP $1,558 12 payments
  2. PROSTEP MICA $898 5 payments
  3. HOFFMANN $150 1 payment
  4. AXOGUARD HA+ NERVE PROTECTOR $45 1 payment
  5. N/A $23 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

341

Median for Orthopedic Surgery: 203

Drug cost

$3,811

Median for Orthopedic Surgery: $1,433

Branded share of claims

10.6%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 75 $1,570
Celecoxib Generic 38 $659
Nitroglycerin Patch Nitroglycerin Brand 11 $521
Methylprednisolone Generic 49 $358
Meloxicam Generic 130 $314
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 11 $209
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 14 $141
Gabapentin Generic 13 $38

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$74,920

Of which drugs: $504

Medicare patients

361

Average age 72

Services billed

4,829

262 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 69%
Depression 29%
Diabetes 25%
Ischemic heart disease 20%
Osteoporosis 18%
Chronic kidney disease 17%
COPD 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 37 3,680 $378
Injection, methylprednisolone acetate, 40 mg J1030 Office 14 27 $126

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

60 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Foot and Ankle Surgery in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record